Related Experiment Video
Updated: May 20, 2026
An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats
Published on: May 8, 2020
Single-cell and spatial transcriptomics identify immune-stromal interactions in cardiac allograft vasculopathy
Macee C Owen1, Daniel Yuhang Li2, Haewon Shin1
1Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Insights
Cardiac allograft vasculopathy (CAV) is a major cause of heart transplant failure. Researchers identified type 1 interferon signaling as a key driver of CAV, suggesting ruxolitinib as a potential targeted therapy.
Area of Science:
- Immunology
- Cardiology
- Transplantation Science
Background:
- Cardiac allograft vasculopathy (CAV) is the primary cause of death after heart transplantation, lacking effective treatments.
- CAV involves neointimal hyperplasia in donor arteries, leading to occlusion and graft failure.
- The cellular and molecular drivers of CAV remain incompletely understood.
Purpose of the Study:
- To characterize the cellular and molecular microenvironment of CAV in human coronary arteries.
- To identify distinct transcriptional signatures associated with CAV.
- To explore potential therapeutic targets for preventing or reversing CAV.
Main Methods:
- Integration of single-cell RNA sequencing and spatial transcriptomics on human coronary arteries.
- Comparative analysis of arteries from CAV patients, atherosclerotic coronary artery disease patients, and non-diseased controls.
- Validation of findings using a mouse model of CAV and blockade of type 1 interferon signaling.
Main Results:
- A unique transcriptional signature for CAV was identified.
- Modulated vascular smooth muscle cells and macrophage subsets were found to dominate the CAV neointima.
- These cell subsets interact to promote type 1 interferon (IFN)-mediated inflammation.
- IFN signaling blockade with ruxolitinib significantly reduced CAV incidence and prolonged allograft survival in a mouse model.
Conclusions:
- The study defines key cellular drivers within the CAV neointima.
- Type 1 interferon signaling is identified as a critical mediator of CAV pathogenesis.
- Targeting IFN signaling, for example, with ruxolitinib, represents a promising therapeutic strategy for CAV.
Abstract:
Cardiac allograft vasculopathy (CAV) is the leading cause of mortality after heart transplantation, yet no targeted therapies exist to prevent or reverse disease progression, and patients with CAV ultimately require a retransplant. CAV is characterized by progressive neointimal hyperplasia in donor coronary arteries, resulting in luminal occlusion and eventual allograft failure. Although immune and stromal cell interactions are thought to drive disease, the key cellular and molecular mechanisms remain poorly defined. Here we integrate single-cell RNA sequencing and spatial transcriptomics of human coronary arteries to characterize the CAV neointimal microenvironment. By comparing arteries with CAV with atherosclerotic coronary artery disease and non-diseased controls, we identify a distinct transcriptional signature of CAV. Our analysis reveals that modulated vascular smooth muscle cells and macrophage subsets dominate the neointima and interact to promote type 1 interferon (IFN)-mediated inflammation. Using a mouse model of CAV, we show that IFN signaling blockade with ruxolitinib significantly reduces CAV incidence and prolongs allograft survival. These findings define key cellular drivers of CAV and highlight IFN signaling as a potential therapeutic target.
